This two-and-a-half day symposium, presented by the American Society of Clinical Oncology, American Society for Radiation Oncology, The Society of Thoracic Surgeons, and the Society for Immunotherapy of Cancer will update participants on the most current, evidence-based practices in thoracic oncology. The symposium will offer an excellent opportunity to refresh, recharge and reconnect with colleagues.
- Equality in medicine
- Multidisciplinary management of brain metastases in the era of effective medical therapies: TKIs, SRS or local therapy; when to use SRS vs hippocampal avoidance WBI; differentiating radiation necrosis from progression
- Neoadjuvant therapies and toxicity challenges
- Optimizing survivorship
On the agenda:
- Non-small Cell Lung Cancer: Questions Raised by Recent Clinical Trials
- Managing Early Stage Lung Cancer
- SCLC: Breakthroughs/Controversies
- Mesothelioma and Thymic Cancer
- Hot Topic: Definitions and Optimal Management of Oligometastatic Disease
- Surveillance Imaging for Lung Cancer
- Progression vs Response After SBRT
- Immunotherapy: Pseudoprogression, Hyperprogression or Progression?
- Why to Wait for Molecular Results Before Initiating Therapy
- Liquid Biopsies and When to Use Them
- Future Directions in Molecular Diagnostics: IO Biomarkers, STK11
Format: Interactive case discussions, educational sessions, debate (Proton vs IMRT), oral abstract sessions, Early-career and Trainee Networking Luncheons (December 2 - Choosing Your Career Path, December 3 - Launching Your Successful Career), poster viewing session, and Q&A sessions.
17 AMA PRA Category 1 Credits™ - maximum
17 ABIM MOC points
Possible contact: firstname.lastname@example.org
Fairmont Scottsdale Princess
December 1-4, 2021
Scottsdale, Arizona 85255, United States